TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
-10.83%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$1.02B
AUM Growth
+$1.02B
(-13%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
10.49%
Top 10 Holdings %
Top 10 Hldgs %
52.04%
Holding
41
New
5
Increased
4
Reduced
2
Closed
3
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$44.9M |
| 2 |
Tango Therapeutics
TNGX
|
$33.2M |
| 3 |
Dianthus Therapeutics
DNTH
|
$32.7M |
| 4 |
Cidara Therapeutics
CDTX
|
$26.1M |
| 5 |
RAPT Therapeutics
RAPT
|
$19.8M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$56.4M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$7.62M |
| 3 |
Keros Therapeutics
KROS
|
$5.21M |
| 4 |
AN2 Therapeutics
ANTX
|
$1.66M |
| 5 |
Adverum Biotechnologies
ADVM
|
$989K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $105M | 10.29% | 3,670,206 | – | – |
|
2
Dyne Therapeutics
DYN
$1.92B
| $62.4M | 6.1% | 2,650,150 | – | – |
|
3
Xencor
XNCR
$580M
| $56.4M | 5.51% | 2,452,138 +25,000 | +1% | +$575K |
|
4
Cogent Biosciences
COGT
$1.69B
| $54.3M | 5.31% | 6,964,375 | – | – |
|
|
CNTA
5
Centessa Pharmaceuticals
CNTA
$2.25B
| $48.4M | 4.73% | 2,890,816 | – | – |
|
6
Ocular Therapeutix
OCUL
$2.12B
| $45.4M | 4.44% | 5,319,148 | – | – |
|
|
UPB
7
Upstream Bio, Inc. Common Stock
UPB
$923M
| $44.9M | 4.38% | +2,801,763 | New | +$44.9M |
|
|
ABVX
8
Abivax
ABVX
$6.12B
| $44.3M | 4.33% | 6,056,596 | – | – |
|
9
Savara
SVRA
$567M
| $38M | 3.71% | 12,362,205 | – | – |
|
|
10
Tango Therapeutics
TNGX
$747M
| $33.2M | 3.24% | +10,736,000 | New | +$33.2M |
|
|
11
Dianthus Therapeutics
DNTH
$759M
| $32.7M | 3.2% | +1,501,624 | New | +$32.7M |
|
12
Disc Medicine
IRON
$2.07B
| $30.9M | 3.02% | 486,957 | – | – |
|
13
Mineralys Therapeutics
MLYS
$1.03B
| $30.4M | 2.97% | 2,470,265 | – | – |
|
14
Tourmaline Bio
TRML
$601M
| $30M | 2.93% | 1,477,593 | – | – |
|
15
Structure Therapeutics
GPCR
$1.11B
| $28.8M | 2.82% | 1,063,000 | – | – |
|
16
Tyra Biosciences
TYRA
$675M
| $27.6M | 2.7% | 1,989,103 | – | – |
|
17
EyePoint Pharmaceuticals
EYPT
$797M
| $26.6M | 2.6% | 3,572,335 +2,650,000 | +287% | +$19.7M |
|
|
18
Cidara Therapeutics
CDTX
$1.66B
| $26.1M | 2.55% | +1,005,901 | New | +$26.1M |
|
|
THRD
19
DELISTED
Third Harmonic Bio
THRD
| $25.8M | 2.52% | 2,505,424 +90,424 | +4% | +$930K |
|
20
Soleno Therapeutics
SLNO
$3.6B
| $24.7M | 2.42% | 550,000 | – | – |
|
21
Astria Therapeutics
ATXS
$349M
| $24.7M | 2.41% | 2,761,861 | – | – |
|
22
Fulcrum Therapeutics
FULC
$351M
| $24.7M | 2.41% | 5,250,000 | – | – |
|
|
SLN
23
Silence Therapeutics
SLN
$227M
| $20.9M | 2.04% | 3,033,560 | – | – |
|
|
24
RAPT Therapeutics
RAPT
$188M
| $19.8M | 1.93% | +13,135,260 | New | +$19.8M |
|
25
Amylyx Pharmaceuticals
AMLX
$836M
| $17.6M | 1.72% | 4,643,812 | – | – |
|